US › Healthcare

Clearpoint Neuro Inc (CLPT)

US · Healthcare · Medical Devices

$13.74+2.54%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

$10.9M

Revenue YoY

+18.1%

Net profit

$-11.3M

EPS

$-0.38

EPS estimate

$-0.29

Net margin

-104.2%

EPS came in at -0.38 against a street estimate of -0.29 — a miss of 31.0%.

Key statistics

Market cap

$418.5M

Forward P/E

12.1

P/B

38.84

Book value

$0.35

EPS (TTM)

$-1.18

52-week high

$30.10

52-week low

$8.27

50-day MA

$15.22

200-day MA

$13.42

Beta

1.27

Analyst view

Analysts rate Clearpoint Neuro Inc a strong buy (2 buy, 0 hold, 0 sell out of 2) with an average price target of $23.50.

Shareholding

Insiders

5.48%

Institutions

52.44%

Largest institutional holders

Fund	Stake
BlackRock Inc	6.83%
Mak Capital One LLC	6.23%
Vanguard Capital Management, LLC	4.08%
Geode Capital Management, LLC	2.31%
State Street Corp	2.23%
The Goldman Sachs Group Inc	1.52%
Lane Generational LLC	1.46%
UBS Group AG	1.42%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Clearpoint Neuro Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.